Advances in the management of patients with IDH-mutant glioma
The Oncologist · 01.12.2025 · 30 (12)
DOI: 10.1093/oncolo/oyaf391 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Oncologist, online erschienen am 24.11.2025. Verfasst von Jessica Rossi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy. Hauptthemen laut MEDLINE: Glioma, Isocitrate Dehydrogenase, Brain Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Isocitrate dehydrogenase (IDH)-mutant gliomas represent a distinct category of diffuse gliomas with unique biological behavior and clinical course. Over the past decade, our understanding of these tumors has dramatically evolved, thanks to advances in molecular classification, imaging, and targeted therapies.
Method
This review provides a comprehensive overview of the current landscape in IDH-mutant glioma management.
Results
We highlight key molecular features and recent refinements in WHO tumor classification, along with novel diagnostic tools such as magnetic resonance spectroscopy and liquid biopsy. Surgical strategies have also shifted, with emphasis on maximal safe resection guided by functional mapping and advanced neuroimaging. Therapeutically, IDH inhibitors like vorasidenib are emerging as promising agents in selected patient populations, offering prolonged disease control. Additionally, radiotherapy and chemotherapy remain critical components, with ongoing trials evaluating their integration with targeted approaches. Finally, we explore future directions, including immunotherapy, PARP inhibitors, and CDK4/6 inhibitors especially in recurrent or treatment-resistant cases.
Conclusions
This review underscores the importance of a multidisciplinary, precision medicine approach in optimizing outcomes for patients with IDH-mutant gliomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.
- Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS of Reggio Emilia, Reggio Emilia, Italy.
- Neurologie 2, Sorbonne Université, Hopital de la Salpétriere, Paris, France.
- Neurosurgery Division, Azienda USL Toscana Nord-ovest, Livorno Hospital, Livorno, Italy.
- Neuroradiology Division, Azienda USL Toscana Nord-ovest, Livorno Hospital, Livorno, Italy.
- Neurology Unit and Neurosurgery Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
ORCID-Profile: Marc Sanson, Anna Luisa Di Stefano
Zitieren
APA
Rossi, J., Picca, A., Santonocito, O. S., Schembari, S., Testaverde, L., Sanson, M., Berzero, G., & Di Stefano, A. L. (2025). Advances in the management of patients with IDH-mutant glioma. The Oncologist, 30(12). https://doi.org/10.1093/oncolo/oyaf391
Vancouver
Rossi J, Picca A, Santonocito OS, Schembari S, Testaverde L, Sanson M, et al. Advances in the management of patients with IDH-mutant glioma. The Oncologist. 2025;30(12). doi:10.1093/oncolo/oyaf391
BibTeX
@article{Rossi2025,
author = {Rossi, Jessica and Picca, Alberto and Santonocito, Orazio Santo and Schembari, Silvia and Testaverde, Lorenzo and Sanson, Marc and Berzero, Giulia and Di Stefano, Anna Luisa},
title = {Advances in the management of patients with IDH-mutant glioma},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {12},
doi = {10.1093/oncolo/oyaf391}
}
EUVIMED